Skip Navigation
Skip to contents

Cancer Res Treat : Cancer Research and Treatment

OPEN ACCESS

Search

Page Path
HOME > Search
5 "Do Hyoung Lim"
Filter
Filter
Article category
Keywords
Publication year
Authors
Original Articles
A Retrospective Analysis for Patients with HER2-Positive Gastric Cancer Who Were Treated with Trastuzumab-Based Chemotherapy: In the Perspectives of Ethnicity and Histology
Jun Ho Yi, Jung Hun Kang, In Gyu Hwang, Hee Kyung Ahn, Hyun Jin Baek, Soon Il Lee, Do Hyoung Lim, Young-Woong Won, Jun Ho Ji, Hyo Song Kim, Sun Young Rha, Sung Yong Oh, Kyung Eun Lee, Taekyu Lim, Chi Hoon Maeng, Moon Jin Kim, Seung Tae Kim, Jeeyun Lee, Joon Oh Park, Young Suk Park, Ho Yeong Lim, Won Ki Kang, Se Hoon Park
Cancer Res Treat. 2016;48(2):553-560.   Published online August 10, 2015
DOI: https://doi.org/10.4143/crt.2015.155
AbstractAbstract PDFPubReaderePub
Purpose
While the Trastuzumab for Gastric Cancer (ToGA) trial demonstrated the efficacy and safety of trastuzumab-based chemotherapy in HER2-positive metastatic gastric cancer, the overall survival (OS) benefit was not found in Asian and diffuse-type cancer patients. The aim of the study is to investigate predictive markers for trastuzumab-based chemotherapy.
Materials and Methods
Data of patients with HER2-positive gastric cancer treated with trastuzumab-based chemotherapy were analyzed retrospectively.
Results
A total of 168 Asian patients were included. The median age was 60 years (range, 27 to 85 years) and the male:female ratio was 118 (70.2%):50 (29.8%). Fourteen (8.3%), 63 (37.5%), 75 (44.6%), and 11 (6.5%) patients had well, moderately, poorly-differentiated tubular adenocarcinoma and signet ring cell carcinoma, respectively. With 14 complete responses and 73 partial responses, the response rate was 50.6%. The median progression-free survival (PFS) was 10.2 months (95% confidence interval [CI], 8.7 to 11.7), and the median OS was 18.5 months (95% CI, 16.4 to 50.6). Next, we investigated the effect of poorly-differentiated histology (PDH, poorly-differentiated tubular adenocarcinoma+signet ring cell carcinoma) on clinical outcomes. The median PFS (8.9 months vs. 11.5 months, p=0.16) was slightly inferior in PDH patients, and the median OS was significantly shorter in PDH patients (14.6 months vs. 19.0 months, p=0.025).
Conclusion
While subset analysis of the ToGA trial demonstrated that trastuzumab-based chemotherapy may not be beneficial for Asians and patients with PDH, our data may suggest that even in Asian patients and patients with PDH, trastuzumab-based chemotherapy could be associated with improved clinical outcomes in patients with HER2-positive gastric cancer.

Citations

Citations to this article as recorded by  
  • Timing to Surgery and Lymph Node Upstaging in Gastric Cancer: An NCDB Analysis
    Maria Cristina Riascos, Jacques A. Greenberg, Federico Palacardo, Rodrigo Edelmuth, V. Colby Lewis, Anjile An, Haythem Najah, Hala Al Asadi, Parima Safe, Brendan M. Finnerty, Paul J. Christos, Thomas J. Fahey, Rasa Zarnegar
    Annals of Surgical Oncology.2024; 31(3): 1714.     CrossRef
  • Deviating HER2 test results in gastric cancer: analysis from the prospective multicenter VARIANZ study
    Katharina Kolbe, Ivonne Haffner, Katrin Schierle, Dieter Maier, Birgitta Geier, Birgit Luber, Hendrik Bläker, Christian Wittekind, Florian Lordick
    Journal of Cancer Research and Clinical Oncology.2023; 149(3): 1319.     CrossRef
  • Trastuzumab Combined With Ramucirumab and Paclitaxel in Patients With Previously Treated Human Epidermal Growth Factor Receptor 2–Positive Advanced Gastric or Gastroesophageal Junction Cancer
    Chang Gon Kim, Minkyu Jung, Hyo Song Kim, Choong-kun Lee, Hei-Cheul Jeung, Dong-Hoe Koo, Woo Kyun Bae, Dae Young Zang, Bum Jun Kim, Hyunki Kim, Un-Jung Yun, Jingmin Che, Sejung Park, Tae Soo Kim, Woo Sun Kwon, Juin Park, Sang Woo Cho, Chung Mo Nam, Hyun C
    Journal of Clinical Oncology.2023; 41(27): 4394.     CrossRef
  • Novel HER2-targeted therapy to overcome trastuzumab resistance in HER2-amplified gastric cancer
    Juin Park, Sun Kyoung Kang, Woo Sun Kwon, Inhye Jeong, Tae Soo Kim, Seo Young Yu, Sang Woo Cho, Hyun Cheol Chung, Sun Young Rha
    Scientific Reports.2023;[Epub]     CrossRef
  • Do proton pump inhibitors affect the effectiveness of chemotherapy in colorectal cancer patients? A systematic review with meta-analysis
    Wan-Ying Lin, Shih-Syuan Wang, Yi-No Kang, Andrea S. Porpiglia, Yu Chang, Chin-Hsuan Huang, Ronak Bhimani, Eahab Abdul-Lattif, Muneeba Azmat, Tsu-Hsien Wang, Yu-Shiuan Lin, Yu-Cheng Chang, Kuan-Yu Chi
    Frontiers in Pharmacology.2022;[Epub]     CrossRef
  • Effectiveness of Trastuzumab in Routine Clinical Practice: A Population-based Study of Patients with HER-2-positive Oesophageal, Gastroesophageal and Gastric Cancer
    S.J. Merchant, W. Kong, B. Gyawali, T. Hanna, W. Chung, S. Nanji, S.V. Patel, C.M. Booth
    Clinical Oncology.2021; 33(3): 202.     CrossRef
  • Trastuzumab-based palliative chemotherapy for HER2-positive gastric cancer: a single-center real-world data
    Tae-Hwan Kim, Hun Do Cho, Yong Won Choi, Hyun Woo Lee, Seok Yun Kang, Geum Sook Jeong, Jin-Hyuk Choi, Mi Sun Ahn, Seung-Soo Sheen
    BMC Cancer.2021;[Epub]     CrossRef
  • HER2 Expression, Test Deviations, and Their Impact on Survival in Metastatic Gastric Cancer: Results From the Prospective Multicenter VARIANZ Study
    Ivonne Haffner, Katrin Schierle, Elba Raimúndez, Birgitta Geier, Dieter Maier, Jan Hasenauer, Birgit Luber, Axel Walch, Katharina Kolbe, Jorge Riera Knorrenschild, Albrecht Kretzschmar, Beate Rau, Ludwig Fischer von Weikersthal, Miriam Ahlborn, Gabriele S
    Journal of Clinical Oncology.2021; 39(13): 1468.     CrossRef
  • Current therapeutic options for gastric adenocarcinoma
    C.R. Akshatha, Smitha Bhat, R. Sindhu, Dharini Shashank, Sarana Rose Sommano, Wanaporn Tapingkae, Ratchadawan Cheewangkoon, Shashanka K. Prasad
    Saudi Journal of Biological Sciences.2021; 28(9): 5371.     CrossRef
  • Efficacy of Trastuzumab and Potential Risk Factors on Survival in Patients with HER2-Positive Metastatic Gastric Cancer
    Atakan Topcu, Muhammed Mustafa Atci, Saban Secmeler, Mehmet Besiroglu, Murat Ayhan, Metin Ozkan, Oktay Bozkurt, Zuhat Urakci, Seval Ay, Caglayan Geredeli, Ayse Irem Yasin, Haci Mehmet Turk
    Future Oncology.2021; 17(31): 4157.     CrossRef
  • Reliability of Conclusions from Early Analyses of Real-World Data for Newly Approved Drugs in Advanced Gastric Cancer in the United States


    Lisa M Hess, Michael Grabner, Liya Wang, Astra M Liepa, Xiaohong Ivy Li, Zhanglin Lin Cui, Lee Bowman, William R Schelman
    Pragmatic and Observational Research.2020; Volume 11: 27.     CrossRef
  • Targeting HER2-positive gastric cancer with a novel 18F-labeled ZHER2:342 probe
    Yunyun Pan, Zhengyang Yang, Yuping Xu, Zhicheng Bai, Donghui Pan, Runlin Yang, Lizhen Wang, Wenxian Guan, Min Yang
    RSC Advances.2019; 9(19): 10990.     CrossRef
  • Clinical significance of overexpression of NRG1 and its receptors, HER3 and HER4, in gastric cancer patients
    Sumi Yun, Jiwon Koh, Soo Kyung Nam, Jung Ok Park, Sung Mi Lee, Kyoungyul Lee, Kyu Sang Lee, Sang-Hoon Ahn, Do Joong Park, Hyung-Ho Kim, Gheeyoung Choe, Woo Ho Kim, Hye Seung Lee
    Gastric Cancer.2018; 21(2): 225.     CrossRef
  • Correlation of trastuzumab-based treatment with clinical characteristics and prognosis in HER2-positive gastric and gastroesophageal junction cancer: A retrospective single center analysis
    A. Ilhan-Mutlu, H. Taghizadeh, A. Beer, W. Dolak, A. Ba-Ssalamah, S. F. Schoppmann, M. Hejna, P. Birner, M. Preusser
    Cancer Biology & Therapy.2018; 19(3): 169.     CrossRef
  • Docetaxel, oxaliplatin, 5FU, and trastuzumab as first-line therapy in patients with human epidermal receptor 2-positive advanced gastric or gastroesophageal junction cancer
    Giandomenico Roviello, Roberto Petrioli, Valerio Nardone, Pietro Rosellini, Andrea Giovanni Multari, Raffaele Conca, Michele Aieta
    Medicine.2018; 97(20): e10745.     CrossRef
  • 14,699 View
  • 168 Download
  • 18 Web of Science
  • 15 Crossref
Close layer
Chemotherapy in Advanced Gastric Cancer Patients Associated with Disseminated Intravascular Coagulation
In Gyu Hwang, Jin Hwa Choi, Se Hoon Park, Sung Yong Oh, Hyuk-Chan Kwon, Soon Il Lee, Do Hyoung Lim, Gyeong-Won Lee, Jung Hun Kang
Cancer Res Treat. 2014;46(1):27-32.   Published online January 15, 2014
DOI: https://doi.org/10.4143/crt.2014.46.1.27
AbstractAbstract PDFPubReaderePub
PURPOSE
Little is known about the clinical features of advanced gastric cancer (AGC) combined with disseminated intravascular coagulation (DIC). The main objective of this study was to determine the clinical outcome of patients with AGC complicated by DIC.
MATERIALS AND METHODS
We conducted a retrospective review of 68 AGC patients diagnosed with DIC at four tertiary medical centers between January 1995 and June 2010.
RESULTS
Sixty eight patients were included. The median age was 55 years (range, 25 to 78 years). Nineteen patients received chemotherapy, whereas 49 patients received only best supportive care (BSC). The median overall survival (OS) of the 68 patients was 16 days (95% confidence interval [CI], 11 to 21 days). Significantly prolonged OS was observed in the chemotherapy group, with a median survival of 61 days compared to 9 days in the BSC group (p<0.001, log-rank test). Age and previous chemotherapy were another significant factors that were associated with OS in univariate analysis. In multivariate analysis, age (> or =65 vs. <65; hazard ratio [HR], 0.38; 95% CI, 0.18 to 0.78; p<0.001), chemotherapy (BSC vs. chemotherapy; HR 0.31; 95% CI, 0.15 to 0.63; p<0.001), and previous chemotherapy (yes or no; HR, 0.49; 95% CI, 0.25 to 0.98; p<0.045) were consistently independent prognostic factors that impacted OS.
CONCLUSION
Our study showed that patients with AGC complicated by DIC had very poor OS, and suggested that chemotherapy might improve OS of these patients.

Citations

Citations to this article as recorded by  
  • Long-term survival of a patient with gastric cancer with bone marrow metastasis receiving S-1 plus oxaliplatin beyond three years: a case report and literature review
    Hirotaka Suto, Yumiko Inui, Atsuo Okamura
    Frontiers in Oncology.2024;[Epub]     CrossRef
  • Metastatic gastric adenocarcinoma discovered in the bone marrow
    Ekaterina Proskuriakova, Vaisny Balamurali, Anuradha Hooda, Paramjeet Khosla
    BMJ Case Reports.2024; 17(9): e260217.     CrossRef
  • Case report: PD-1 inhibitor-based treatment strategies in gastric cancer complicated by bone marrow metastasis and disseminated intravascular coagulation: A report of two cases
    Ren-Ze Huang, Nuo Chen, Yan Hu, Wan-Ming Hu, Feng-Hua Wang, Dong-Liang Chen
    Frontiers in Oncology.2023;[Epub]     CrossRef
  • Comparative analysis of systemic oncological treatments and best supportive care for advanced gastresophageal cancer: A comprehensive scoping review and evidence map
    Santero Marilina, Meade Adriana, Selva Anna, Acosta‐Dighero Roberto, Meza Nicolás, Quintana Maria Jesús, Bracchiglione Javier, Requeijo Carolina, Salazar Josefina, Rodríguez Grijalva Gerardo, Solà Ivan, Urrútia Gerard, Bonfill Cosp Xavier
    Journal of Evidence-Based Medicine.2023; 16(2): 216.     CrossRef
  • Clinicopathologic features and prognosis of 71 patients with gastric cancer and disseminated intravascular coagulation
    Ling Chen, Jing Lin, Yu Chen, Jiami Yu, Xiaojie Wang
    PeerJ.2023; 11: e16527.     CrossRef
  • Docetaxel and Fluorouracil as First-Line Therapy for Gastric Cancer with Bone Marrow Metastasis and Disseminated Intravascular Coagulation
    Zhai Xiaohui, Li Shanshan, Cao Taiyuan, Du Ge, Yu Hongen, Shi Lishuo, Lin Xiaoru, Hong Wanjia, Xiao Jian
    Future Oncology.2022; 18(35): 3875.     CrossRef
  • A Clot Waveform Analysis Showing a Hypercoagulable State in Patients with Malignant Neoplasms
    Mayu Kobayashi, Hideo Wada, Shunsuke Fukui, Hiroki Mizutani, Yuhuko Ichikawa, Katsuya Shiraki, Isao Moritani, Hidekazu Inoue, Motomu Shimaoka, Hideto Shimpo
    Journal of Clinical Medicine.2021; 10(22): 5352.     CrossRef
  • Understanding and treating solid tumor–related disseminated intravascular coagulation in the “era” of targeted cancer therapies
    Felice Vito Vitale, Giuseppe SA Longo-Sorbello, Stefano Rotondo, Francesco Ferrau
    SAGE Open Medicine.2017;[Epub]     CrossRef
  • Advanced gastric cancer linitis plastica presented with disseminated intravascular coagulation
    Sehem Ghazala, Jawad Bilal, Irbaz Bin Riaz
    BMJ Case Reports.2016; : bcr2016217675.     CrossRef
  • Efficacy and Safety of Weekly Paclitaxel Therapy for Advanced Gastric Cancer Patients with Disseminated Intravascular Coagulation
    Sadayuki Kawai, Yasuhiro Sakamoto, Yoshikazu Takahashi, Sonoko Ichikawa, Makio Gamoh
    Journal of Gastrointestinal Cancer.2015; 46(4): 438.     CrossRef
  • D-Dimer Can Serve as a Prognostic and Predictive Biomarker for Metastatic Gastric Cancer Treated by Chemotherapy
    Se-Il Go, Min Jeong Lee, Won Sup Lee, Hye Jung Choi, Un Seok Lee, Rock Bum Kim, Myoung Hee Kang, Hoon-Gu Kim, Gyeong-Won Lee, Jung Hun Kang, Jeong-Hee Lee, Sun Joo Kim
    Medicine.2015; 94(30): e951.     CrossRef
  • 13,928 View
  • 103 Download
  • 13 Web of Science
  • 11 Crossref
Close layer
A Retrospective Study of First-Line Combination Chemotherapy in Advanced Colorectal Cancer: A Korean Single-Center Experience
Soon Il Lee, Se Hoon Park, Do Hyoung Lim, Keon Woo Park, Jeeyun Lee, Joon Oh Park, Young Suk Park, Ho Yeong Lim, Won Ki Kang
Cancer Res Treat. 2011;43(2):96-101.   Published online June 30, 2011
DOI: https://doi.org/10.4143/crt.2011.43.2.96
AbstractAbstract PDFPubReaderePub
PURPOSE
Fluoropyrimidine-based combination chemotherapy, in combination with either oxaliplatin or irinotecan, has demonstrated efficacy and tolerability in treatment of advanced colorectal cancer (ACC).
MATERIALS AND METHODS
Between January 2006 and December 2007, a total of 478 ACC patients were treated with combination chemotherapy in first-line settings. Combination therapies included: 5-fluorouracil, folinic acid plus oxaliplatin (FOLFOX, n=172), 5-fluorouracil, folinic acid plus irinotecan (FOLFIRI, n=95), capecitabine plus oxaliplatin (XELOX, n=155), and capecitabine plus irinotecan (XELIRI, n=56). FOLFOX and FOLFIRI were repeated every 2 weeks, whereas XELOX and XELIRI were repeated every 3 weeks until occurrence of disease progression or unacceptable toxicity, or until a patient chose to discontinue treatment.
RESULTS
The median age was 58 years (range, 19 to 84 years) and the median chemotherapy durations for FOLFOX, FOLFIRI, XELOX, and XELIRI were 4.9, 4.5, 5.7, and 5.4 months, respectively. Combination chemotherapy regimens were generally well tolerated. The estimated median progression-free-survival (PFS) for all patients was 6.8 months (95% confidence interval, 6.3 to 7.3 months). No statistically significant difference in PFS was found among regimens used as first-line chemotherapy. Sixty percent (n=290) of patients received second or further lines of therapy after failure.
CONCLUSION
Fluoropyrimidine-based combination chemotherapy regimens appear to be equally active and tolerable as first-line therapy for ACC.

Citations

Citations to this article as recorded by  
  • Nineteen-year, real-world experience of first-line combination chemotherapy in patients with metastatic colorectal cancer: a propensity score analysis from southern Thailand
    Jirapat Wonglhow, Chirawadee Sathitruangsak, Arunee Dechaphunkul, Patrapim Sunpaweravong
    Journal of International Medical Research.2023;[Epub]     CrossRef
  • Polymorphisms in TYMS for Prediction of Capecitabine-Induced Hand-Foot Syndrome in Chinese Patients with Colorectal Cancer
    Si-Qi Dong, Tong-Min Wang, Jiang-Bo Zhang, Yong-Qiao He, Wen-Qiong Xue, Zi-Yi Wu, Da-Wei Yang, Lian-Jing Cao, Jing-Wen Huang, Xi-Zhao Li, Pei-Fen Zhang, Xiao-Hui Zheng, Wei-Hua Jia
    Cancer Research and Treatment.2021; 53(3): 724.     CrossRef
  • 10,695 View
  • 75 Download
  • 2 Crossref
Close layer
Case Reports
Three Cases of Synchronous Solid Tumor and Multiple Myeloma
Sang Hoon Ji, Joon Oh Park, Jeeyun Lee, Mi Jung Oh, Do Hyoung Lim, Byeong-Bae Park, Keun Woo Park, Se-Hoon Lee, Kihyun Kim, Won Seog Kim, Chul Won Jung, Young Suk Park, Young-Hyuck Im, Won Ki Kang, Mark H Lee, Keunchil Park
Cancer Res Treat. 2004;36(5):338-340.   Published online October 31, 2004
DOI: https://doi.org/10.4143/crt.2004.36.5.338
AbstractAbstract PDFPubReaderePub

The association between a multiple myeloma and a secondary solid tumor is not well established. Some reports showed an increased risk of secondary solid neoplasms in multiple myeloma patients, but others have not. Three cases of the synchronous occurrence of multiple myelomas and solid tumors, namely, a small cell carcinoma of the lung, an adenocarcinoma of the colon and a squamous carcinoma of the pyriform sinus were experienced at our hospital. Therefore, herein is reported the clinical courses and treatment results. The stage of multiple myeloma was Durie-Salmon stage I in all of three cases; therefore, the solid tumors were treated as a primary target because the prognosis of early stage multiple myeloma is generally better than that of advanced solid tumor, while a smoldering or stage I myeloma do not need primary therapy until progression of the multiple myeloma. Two patients died of their solid tumors, but one patient is alive.

Citations

Citations to this article as recorded by  
  • Three-year progression-free survival of a patient with concomitant mucinous adenocarcinoma of the colon with peritoneal dissemination and multiple myeloma who received lenalidomide: a case report
    Koki Tamai, Hajime Hirose, Yo Akazawa, Yukihiro Yoshikawa, Masatoshi Nomura, Hiroshi Takeyama, Masahiro Tokunaga, Mitsuyoshi Tei, Shu Okamura, Yusuke Akamaru
    Surgical Case Reports.2024;[Epub]     CrossRef
  • The importance of oncological alertness in the differential diagnosis of inflammatory changes in the lungsdetected as a result of differential diagnosis of pneumonia
    M. F. Petrukhnova, O. O. Voronkova, O. E. Buyanova, O. N. Antyufeeva, A. E. Kamalova, M. V. Kozhevnikova, I. S. Ilgisonis, Yu. N. Belenkov
    Meditsinskiy sovet = Medical Council.2024; (9): 100.     CrossRef
  • Synchronous multiple myeloma and lung adenocarcinoma: A clinical series
    Fang Ye, Huan Wang, Ningning Li, Aijun Liu, Wenming Chen
    Indian Journal of Pathology and Microbiology.2024; 67(2): 390.     CrossRef
  • Simultaneous multiple myeloma and non‑small cell lung carcinoma: A case report and review of the literature
    Huan-Huan Dong, Jing Li, Lin Kang, Qiang Wei, Yan Li
    Oncology Letters.2022;[Epub]     CrossRef
  • Rapid progression of gastric cancer with liver metastasis after discontinuation of lenalidomide in a patient with concurrent multiple myeloma: A case report
    Naoto Ujiie, Yoshitaka Enomoto, Naruhito Takido, Yasushi Kawaharada, Masashi Zuguchi, Yosuke Kubota
    International Journal of Surgery Case Reports.2021; 81: 105834.     CrossRef
  • Bortezomib combined with lenalidomide as the first-line treatment for the rare synchronous occurrence of multiple myeloma and pulmonary adenocarcinoma
    Wenli Zuo, Xinghu Zhu, Jingke Yang, Zhenyang Mei, Mei Deng, Quande Lin, Yongping Song, Qingsong Yin
    Medicine.2017; 96(1): e5787.     CrossRef
  • Drastic Response to Nivolumab in a Case Demonstrating a Rapid Recurrence of Pulmonary Pleomorphic Carcinoma That Developed After Chemotherapy for Comorbid Myeloma Kidney
    Aya Yamamoto, Takashi Iwata, Koji Hashimoto
    Haigan.2017; 57(7): 849.     CrossRef
  • Challenges in managing a patient with multiple primary malignancies
    Nataliya Mar, David Askin, Jerry George, Colette Spaccavento, Robert Graham, Lynn Ratner
    Community Oncology.2012; 9(12): 377.     CrossRef
  • ¿Asociación entre colangiocarcinoma y mieloma múltiple?
    Laura Gómez-Escolar Viejo, Gema Soler Sala, Vanessa Castaño Giraldo, José María Palazón Azorín, Miguel Pérez-Mateo Regadera
    Gastroenterología y Hepatología.2008; 31(6): 402.     CrossRef
  • Synchronous Presentation of Multiple Myeloma and Lung Cancer
    Rishu Agarwal, Ritu Gupta, Archana Bhaskar, Atul Sharma, Sanjay Thulkar, Lalit Kumar
    Journal of Clinical Oncology.2008; 26(35): 5814.     CrossRef
  • 10,383 View
  • 54 Download
  • 10 Crossref
Close layer
Esophageal Squamous Cell Carcinoma Recurring as a Solitary Renal Mass
Do Hyoung Lim, Young-Hyuck Im, Sang Hoon Ji, Byeong-Bae Park, Mi Jung Oh, Jeeyun Lee, Keun Woo Park, Se-Hoon Lee, Joon-Oh Park, Kihyun Kim, Won Seog Kim, Chul Won Jung, Young Suk Park, Won Ki Kang, Mark H Lee, Kwanmien Kim, Young Mog Shim, Keunchil Park
Cancer Res Treat. 2004;36(4):271-274.   Published online August 31, 2004
DOI: https://doi.org/10.4143/crt.2004.36.4.271
AbstractAbstract PDFPubReaderePub

Herein, a case of solitary, unilateral renal metastasis in a patient with curatively resected thoracic esophageal carcinoma, who achieved a pathological complete remission after neoadjuvant concurrent chemoradiotherapy, is reported. The kidney is the 4th or 5th most common visceral metastasis site of a primary esophageal carcinoma. More than 50% of renal metastases typically show bilateral involvement. Solitary, unilateral renal metastasis is extremely rare. Renal metastases from a primary esophageal carcinoma are usually latent and its diagnosis is very unusual in a live patient. The solitary renal metastasis in this case was not accompanied by metastases to other sites. The value of a nephrectomy in solitary renal metastasis of esophageal cancer is not known due to the rarity of such cases. A nephrectomy could be justified in limited situations, such as with uncertainty of histological diagnosis, severe life-threatening hematuria, which cannot be controlled by embolization, or solitary renal metastasis with a long disease-free interval.

Citations

Citations to this article as recorded by  
  • Rapidly Rising Serum Creatinine in a Patient With Colorectal Adenocarcinoma and Eosinophilia: A Quiz
    Athiphat Banjongjit, Vorachai Ratanatharathorn, Piyanut Mahanupap, Winyou Mitarnun
    American Journal of Kidney Diseases.2024; 83(2): A14.     CrossRef
  • Esophageal squamous cell carcinoma metastases to kidney and renal hilar lymph nodes through epithelial-mesenchymal transition: a case report and literature review
    Nai-Jun Fan
    American Journal of Translational Research.2024; 16(5): 1825.     CrossRef
  • Secondary Tumors of the Kidney: A Comprehensive Clinicopathologic Analysis
    Faisal Saeed, Adeboye O. Osunkoya
    Advances in Anatomic Pathology.2022; 29(4): 241.     CrossRef
  • Surgery for metachronous oligometastatic esophageal cancer: Is there enough evidence?
    Dimitrios Schizas, Michail Vailas, Maria Sotiropoulou, Ioannis A. Ziogas, Konstantinos S. Mylonas, Ioannis Katsaros, Alkistis Kapelouzou, Theodore Liakakos
    Cirugía Española.2021; 99(7): 490.     CrossRef
  • Surgery for metachronous oligometastatic esophageal cancer: Is there enough evidence?
    Dimitrios Schizas, Michail Vailas, Maria Sotiropoulou, Ioannis A. Ziogas, Konstantinos S. Mylonas, Ioannis Katsaros, Alkistis Kapelouzou, Theodore Liakakos
    Cirugía Española (English Edition).2021; 99(7): 490.     CrossRef
  • The role of surgical treatment in isolated organ recurrence of esophageal cancer—a systematic review of the literature
    Dimitrios Schizas, Ioannis I. Lazaridis, Demetrios Moris, Aikaterini Mastoraki, Lazaros-Dimitrios Lazaridis, Diamantis I. Tsilimigras, Nikolaos Charalampakis, Theodore Liakakos
    World Journal of Surgical Oncology.2018;[Epub]     CrossRef
  • Esophageal Cancer with Solitary Renal Metastasis Treated with Multidisciplinary Therapy: A Case Report and Mini Review of the Literature
    Kyoung Sik Nam, Kyoungwon Jung, Moo In Park, Seun Ja Park, Won Moon, Sung Eun Kim, Jae Hyun Kim
    The Korean Journal of Helicobacter and Upper Gastrointestinal Research.2017; 17(1): 39.     CrossRef
  • Esophageal Cancer Metastases to Unexpected Sites: A Systematic Review
    Osama Shaheen, Abdulaziz Ghibour, Bayan Alsaid
    Gastroenterology Research and Practice.2017; 2017: 1.     CrossRef
  • FDG PET/CT in 2 Cases of Renal Metastasis From Esophageal Squamous Cell Carcinoma
    Qian Zhao, Aisheng Dong, Bo Yang, Yang Wang, Changjing Zuo
    Clinical Nuclear Medicine.2017; 42(11): 896.     CrossRef
  • Solitary renal metastasis of esophageal squamous cell carcinoma mimicking primary renal neoplasm – A case report and literature review
    Kai-Po Chang, Chi-Ping Huang, Han Chang
    BioMedicine.2016;[Epub]     CrossRef
  • Unilateral renal metastases after definitive chemoradiation in squamous cell carcinoma of esophagus: A case report and review literature
    Kapil Dev, Jaiprakash Gurawalia, Sandeep Nayak, Balu Sadasivan
    Asian Journal of Oncology.2016; 02: 046.     CrossRef
  • Renal metastasis after esophagectomy of esophageal squamous cell carcinoma: a case report and literature review
    Yan Sun, Xinmin Yu, Yiping Zhang
    World Journal of Surgical Oncology.2014;[Epub]     CrossRef
  • Esophageal Adenocarcinoma with Solitary Renal Metastasis
    Thomas D. Willson, Matthew J. Blecha, Mark M. Connolly, Francis J. Podbielski
    Journal of Gastrointestinal Cancer.2013; 44(3): 351.     CrossRef
  • Synchronous Squamous Cell Carcinomas of the Esophagus and Renal Pelvis
    Te-Chun Hsieh, Yu-Chin Wu, Shung-Shung Sun, I-Ping Chiang, Chun-Fan Yang, Kuo-Yang Yen, Chia-Hung Kao
    Clinical Nuclear Medicine.2011; 36(11): e171.     CrossRef
  • 9,861 View
  • 62 Download
  • 14 Crossref
Close layer

Cancer Res Treat : Cancer Research and Treatment
Close layer
TOP